Outcomes	O

The	O
primary	O
outcome	O
was	O
a	O
composite	O
of	O
mechanical	B-PrimaryOutcome
ventilation	I-PrimaryOutcome
,	I-PrimaryOutcome
hospitalization	I-PrimaryOutcome
>	I-PrimaryOutcome
14	I-PrimaryOutcome
days	I-PrimaryOutcome
or	I-PrimaryOutcome
in	I-PrimaryOutcome
-	I-PrimaryOutcome
hospital	I-PrimaryOutcome
death	I-PrimaryOutcome
.	O

Secondary	O
outcomes	O
included	O
:	O
days	B-SecondaryOutcome
of	I-SecondaryOutcome
mechanical	I-SecondaryOutcome
ventilation	I-SecondaryOutcome
,	O
days	B-SecondaryOutcome
of	I-SecondaryOutcome
high	I-SecondaryOutcome
-	I-SecondaryOutcome
flow	I-SecondaryOutcome
nasal	I-SecondaryOutcome
cannula	I-SecondaryOutcome
(	I-SecondaryOutcome
HFNC	I-SecondaryOutcome
)	I-SecondaryOutcome
,	O
days	B-SecondaryOutcome
of	I-SecondaryOutcome
oxygen	I-SecondaryOutcome
requirement	I-SecondaryOutcome
,	O
time	B-SecondaryOutcome
to	I-SecondaryOutcome
respiratory	I-SecondaryOutcome
failure	I-SecondaryOutcome
development	I-SecondaryOutcome
(	I-SecondaryOutcome
PaO2	I-SecondaryOutcome
/	I-SecondaryOutcome
FiO2	I-SecondaryOutcome
<	I-SecondaryOutcome
200	I-SecondaryOutcome
)	I-SecondaryOutcome
,	O
the	O
severity	B-SecondaryOutcome
of	I-SecondaryOutcome
multiple	I-SecondaryOutcome
organ	I-SecondaryOutcome
dysfunction	I-SecondaryOutcome
(	I-SecondaryOutcome
by	I-SecondaryOutcome
SOFA	I-SecondaryOutcome
score	I-SecondaryOutcome
)	I-SecondaryOutcome
at	B-TimeFrame
day	I-TimeFrame
3	I-TimeFrame
and	I-TimeFrame
7	I-TimeFrame
;	O
days	B-SecondaryOutcome
in	I-SecondaryOutcome
ICU	I-SecondaryOutcome
or	I-SecondaryOutcome
intermediate	I-SecondaryOutcome
care	I-SecondaryOutcome
unit	I-SecondaryOutcome
,	I-SecondaryOutcome
hospital	B-SecondaryOutcome
length	I-SecondaryOutcome
of	I-SecondaryOutcome
stay	I-SecondaryOutcome
,	O
and	O
mortality	B-SecondaryOutcome
at	B-TimeFrame
30	I-TimeFrame
days	I-TimeFrame
.	O

The	O
kinetics	O
of	O
inflammatory	O
biomarkers	O
,	O
including	O
total	B-SecondaryOutcome
lymphocyte	I-SecondaryOutcome
count	I-SecondaryOutcome
,	O
C	B-SecondaryOutcome
-	I-SecondaryOutcome
reactive	I-SecondaryOutcome
protein	I-SecondaryOutcome
(	I-SecondaryOutcome
CRP	I-SecondaryOutcome
)	I-SecondaryOutcome
,	O
procalcitonin	B-SecondaryOutcome
,	O
LDH	B-SecondaryOutcome
,	O
D	B-SecondaryOutcome
-	I-SecondaryOutcome
dimer	I-SecondaryOutcome
,	O
ferritin	B-SecondaryOutcome
and	O
IL	B-SecondaryOutcome
-	I-SecondaryOutcome
6	I-SecondaryOutcome
were	O
determined	O
on	B-TimeFrame
days	I-TimeFrame
0	I-TimeFrame
,	I-TimeFrame
3	I-TimeFrame
and	I-TimeFrame
7	I-TimeFrame
;	O
and	O
SARS	B-SecondaryOutcome
-	I-SecondaryOutcome
CoV	I-SecondaryOutcome
-	I-SecondaryOutcome
2	I-SecondaryOutcome
RT	I-SecondaryOutcome
-	I-SecondaryOutcome
PCR	I-SecondaryOutcome
in	O
nasopharyngeal	O
swab	O
on	B-TimeFrame
days	I-TimeFrame
3	I-TimeFrame
and	I-TimeFrame
7	I-TimeFrame
.	O

Radiological	O
outcomes	O
included	O
the	O
comparison	B-SecondaryOutcome
of	I-SecondaryOutcome
infiltrates	I-SecondaryOutcome
progression	I-SecondaryOutcome
on	I-SecondaryOutcome
chest	I-SecondaryOutcome
CT	I-SecondaryOutcome
scans	I-SecondaryOutcome
on	B-TimeFrame
enrollment	I-TimeFrame
and	I-TimeFrame
day	I-TimeFrame
5	I-TimeFrame
,	O
based	O
on	O
COVID	O
-	O
19	O
pneumonia	O
severity	O
scores	O
[	O
20	O
–	O
23	O
]	O
.	O

For	O
the	O
combined	O
analysis	O
with	O
portable	O
chest	O
X	O
-	O
rays	O
,	O
a	O
blinded	O
thoracic	O
radiologist	O
expert	O
categorized	O
images	O
as	O
“	O
progression	O
”	O
vs	O
“	O
stable	O
or	O
improved	O
”	O
.	O

Also	O
,	O
pre	O
-	O
planned	O
analyses	O
of	O
baseline	O
neutralizing	B-UnclearOutcome
antibodies	I-UnclearOutcome
(	I-UnclearOutcome
NAbs	I-UnclearOutcome
)	I-UnclearOutcome
titers	I-UnclearOutcome
,	O
and	O
anti	B-UnclearOutcome
-	I-UnclearOutcome
SARS	I-UnclearOutcome
-	I-UnclearOutcome
CoV	I-UnclearOutcome
-	I-UnclearOutcome
2	I-UnclearOutcome
IgG	I-UnclearOutcome
titers	I-UnclearOutcome
were	O
determined	O
in	O
participants	O
from	O
the	O
early	O
plasma	O
group	O
and	O
in	O
the	O
subset	O
of	O
participants	O
from	O
the	O
deferred	O
plasma	O
group	O
who	O
had	O
not	O
yet	O
received	O
plasma	O
on	O
days	B-TimeFrame
0	I-TimeFrame
,	I-TimeFrame
3	I-TimeFrame
and	I-TimeFrame
7	I-TimeFrame
.	O

Analysis	O
of	O
the	O
primary	O
outcome	O
and	O
clinical	O
secondary	O
outcomes	O
was	O
performed	O
by	O
intention	O
-	O
to	O
-	O
treat	O
(	O
ITT	O
)	O
.	O

Laboratory	O
and	O
radiology	O
secondary	O
outcomes	O
were	O
analyzed	O
by	O
modified	O
-	O
ITT	O
,	O
excluding	O
a	O
patient	O
who	O
withdrew	O
consent	O
before	O
any	O
intervention	O
.	O

Safety	O
outcomes	O
were	O
evaluated	O
in	O
all	O
participants	O
.	O

